Celldex Therapeutics | CLDX - Selling And Administration Expenses

Stock Price
29.51
Daily Change
4.67 18.78%
Monthly
11.05%
Yearly
41.85%
Q1 Forecast
22.31

Celldex Therapeutics reported $6.63M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Agenus USD 23.6M 448K Sep/2025
Amgen USD 1.94B 237M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Celldex Therapeutics USD 6.63M 546K Sep/2025
Glaxosmithkline GBP 2.91B 817.89M Sep/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Northwest Biotherapeutics USD 7.03M 534K Sep/2023
Pfizer USD 4.08B 894M Dec/2025
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Roche Holding CHF 7.28B 3.99B Dec/2025